Congenital Hyperinsulinism

Disease Overview

Congenital Hyperinsulinism (CHI) is a rare genetic disorder characterized by uncontrolled insulin secretion from pancreatic beta cells, resulting in persistent and potentially dangerous hypoglycemia. This condition can cause significant neurological complications if not promptly diagnosed and managed, potentially leading to permanent brain damage.

Disease Category

Rare Genetic Endocrine and Metabolic Disorder

Synonyms

Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Nesidioblastosis
Pancreatic Nesidioblastosis
Familial Hyperinsulinism

Signs & Symptoms

Severe and recurrent hypoglycemia in newborns and infants
Neurological symptoms during hypoglycemic episodes:
- Jitteriness
- Lethargy
- Irritability
- Poor feeding
- Seizures
- Potential loss of consciousness
Risk of developmental delays
Potential long-term neurological impairment
Sweating
Pallor
Weakness
Altered mental status

Causes

Genetic Mutations Affecting Insulin Regulation: - Primary genetic mutations in: - ABCC8 gene - KCNJ11 gene - GLUD1 gene - GCK gene - HADH gene - HNF4A gene - UCP2 gene

Disease Forms: - Diffuse form: Insulin overproduction throughout pancreas - Focal form: Localized insulin-producing area in pancreas - Autosomal recessive inheritance pattern

Affected Populations

Primarily affects neonates and infants
Equal gender distribution
Higher incidence in populations with:
- High consanguinity rates
- Ashkenazi Jewish descent
- Saudi Arabian descent
Estimated prevalence: 1 in 50,000 live births

Disorders with Similar Symptoms

Insulinoma
Congenital Glycosylation Disorders
Ketotic Hypoglycemia
Addison's Disease
Other metabolic disorders causing hypoglycemia

Diagnosis

Diagnostic Criteria: - Blood glucose levels below 50-60 mg/dL - Inappropriately high insulin levels during hypoglycemia - Genetic testing for mutation identification - Imaging studies: - CT scan - MRI - Positron Emission Tomography - Potential pancreatic biopsy - Comprehensive metabolic panel - Hormone level assessments

Standard Therapies

Medical Management: - Intravenous glucose administration - Medications: - Diazoxide - Octreotide (somatostatin analog) - Nifedipine - Frequent feeding protocols - Continuous glucose monitoring

Surgical Interventions: - Partial pancreatectomy - Near-total pancreatectomy - Selective adenoma removal (in focal cases)

Clinical Trials and Studies

Ongoing genetic research
Novel medication development
Surgical technique improvements
Gene therapy investigations
Recommended resources:
- ClinicalTrials.gov
- NIH Clinical Trials Registry

References

National Institutes of Health
Genetic and Rare Diseases Information Center
Pediatric Endocrinology journals
International CHI research publications

Programs & Resources

Congenital Hyperinsulinism International
Hyperinsulinism Center at Children's Hospital of Philadelphia
Genetic and Rare Diseases Information Center
Online support communities
Patient advocacy groups

Complete Report

A comprehensive overview of Congenital Hyperinsulinism highlighting its complex genetic, clinical, and management aspects. Continuous medical research and personalized treatment approaches are crucial for improving patient outcomes.

Note: Always consult specialized medical professionals for personalized medical advice and treatment strategies.